Figure 1.

Patient-derived bladder cancer xenograft (PDX) tumors BL0293 and BL0440 relapse following combination drug therapy. (A) Drug dosing was initiated when tumors reached ~100–150 mm³ in size and occurred over 21 days with experimental mice (drug treated (Rx)) (n = 5) and phosphate buffered saline (PBS) control mice (n = 3) treated concurrently with gemcitabine (intraperitoneally) and cisplatin (intravenously). Tumor growth was measured weekly for (B) BL0293 and (C) BL0440. RNA was isolated from PBS and Rx tumors at last time point recorded.